In summary, TGFβ can thus be seen as a relevant antagonist of the immunological control of CRC disease, both by limiting the presence of cytolytic effector immune cells in the tumor and by promoting the T cell-mediated secretion of pro-tumorigenic cytokines. Here, TGFB1 is linked to neoplasm.